Screener
Rhythm Pharmaceuticals, Inc. RYTM Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $71.26M+46.9% | $60.11M+83.8% | $57.25M+36.9% | $51.3M+54.3% | $48.5M+66.8% | ||
| $8.93M+61.1% | $7.16M+96.2% | $4.8M+26.8% | $5.5M+43.7% | $5.54M+88.1% | ||
| $62.32M+45.1% | $52.96M+82.3% | $52.45M+37.9% | $45.8M+55.7% | $42.96M+64.4% | ||
| 87.5%-1.1pp | 88.1%-0.8pp | 91.6%+0.7pp | 89.3%+0.8pp | 88.6%-1.3pp | ||
| $43.43M+2.6% | $41.73M+12.9% | $42.03M+2.1% | $46.03M+21.3% | $42.31M+40.1% | ||
| $67.45M+46.8% | $63.59M+62.7% | $57.48M+50.8% | $52.43M+48.2% | $45.95M+26.2% | ||
| $119.81M+27.7% | $112.47M+41.1% | $104.32M+25.6% | $103.95M+34.8% | $93.8M+34.9% | ||
| -$48.55M-7.2% | -$52.36M-11.4% | -$47.06M-14.1% | -$52.65M-20.0% | -$45.3M-11.9% | ||
| -68.1%+25.3pp | -87.1%+56.6pp | -82.2%+16.4pp | -102.6%+29.3pp | -93.4%+45.8pp | ||
| $4.54M-22.0% | $4.58M-15.3% | $4.62M-15.3% | $4.74M-9.5% | $5.82M+26.4% | ||
| -$302K+69.8% | -$2.73M-13.2% | -$473K— | -$140K-40.0% | -$999K-111% | ||
| -$48.85M-5.5% | -$55.09M-11.5% | -$47.54M-9.6% | -$52.79M-20.0% | -$46.3M-45.7% | ||
| $444K+31.8% | $545K+581% | $0— | $111K+132% | $337K-29.6% | ||
| -$49.3M-5.7% | -$55.64M-12.4% | -$47.51M-9.7% | -$52.9M-21.2% | -$46.63M-44.5% | ||
| -69.2%+27.0pp | -92.6%+58.8pp | -83%+20.5pp | -103.1%+28.1pp | -96.1%+14.8pp | ||
| -$0.73+2.7% | -$0.83-2.5% | -$0.73-1.4% | -$0.82-12.3% | -$0.75-36.4% | ||
| -$48.55M-7.2% | -$52.36M-11.4% | -$47.06M-14.1% | -$52.65M-20.0% | -$45.3M-11.9% |
FAQ
- What is Rhythm Pharmaceuticals, Inc.'s revenue?
- Rhythm Pharmaceuticals, Inc. (RYTM) generated $239.9M in revenue over the trailing twelve months, up 53.5% year over year.
- Is Rhythm Pharmaceuticals, Inc. profitable?
- Rhythm Pharmaceuticals, Inc. is not currently profitable: it reported a net loss of $205.3M over the trailing twelve months, a -85.6% net margin.
- What are Rhythm Pharmaceuticals, Inc.'s profit margins?
- Gross margin is 89.0% and operating margin is -83.6%, with a -85.6% net margin.
- What is Rhythm Pharmaceuticals, Inc.'s earnings per share?
- Rhythm Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $-3.11.
- Where does Rhythm Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from Rhythm Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
